Results 31 to 40 of about 6,026 (204)
Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]
, 2015 Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti +142 more
core +2 more sources
Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. [PDF]
, 2019 BACKGROUND: Carbapenems are β-lactam antibiotics which are used to treat severe infections caused by multidrug resistant Enterobacteriacea. The recent emergence and rapid spread of Enterobacteriaceae resistant to carbapenems is a global concern.
Ding, Y +4 more
core +1 more source
Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients with Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy during the COVID-19 Pandemic [PDF]
, 2023 Background: Carbapenem-resistant Acinetobacter baumannii infections are difficult to treat and are a significant public health threat due to intrinsic/acquired resistance and limited treatment options. Methods: A retrospective, observational cohort study
Abdel Hadi H. +8 more
core +1 more source
The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]
, 2018 The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core +1 more source
Microbiology Spectrum, 2023 In this study, we aimed to comparatively evaluate the in vitro activity of cefiderocol versus other antimicrobials against a well-characterized collection of metallo-beta-lactamase (MBL)-producing Gram-negative bacilli (MBL-GNB) isolates from hospitals ...
M. Delgado-Valverde +4 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 : Objectives: The incidence of antimicrobial resistance in Europe is rising. Cefiderocol is approved in Europe for treatment of aerobic Gram-negative bacterial (GNB) infections in adults with limited treatment options. We report the in vitro activity of
Emilia Cercenado +5 more
doaj +1 more source
Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance
Nature Communications, 2023 The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe ...
Chenyuan Wang +9 more
doaj +1 more source
Antibacterial spectrum of cefiderocol
Revista Española de Quimioterapia, 2022 Cefiderocol, a siderophore catechol cephalosporin, recently introduced in the market has been developed to enhance the in vitro activity of extended spectrum cephalosporins and to avoid resistance mechanisms affecting cephalosporins and carbapenems. The in vitro study of cefiderocol in the laboratory requires iron depleted media when MIC values are ...
Cordero, Desirée Gijón +3 more
openaire +2 more sources
Journal of Global Antimicrobial Resistance, 2021 Objectives: The aim of this study was to investigate the clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections. Methods: The PubMed, Embase and Cochrane Library databases as well as the clinical trials registries of ...
Shun-Chung Hsueh +4 more
doaj +1 more source
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study [PDF]
, 2021 open16noFunding: This study was carried out as part of our routine work and supported by internal funding.Objectives: To analyse the impact of cefiderocol use on outcome in patients admitted to the ICU for severe COVID-19 and further diagnosed with ...
Ambretti, Simone +15 more
core +1 more source